

## Aoxing Pharmaceutical Company, Inc.

Flat F, 9/F, Block 25, South Horizons,  
Apleichau, Hong Kong

---

+852 9491-2348

frankiecflo@outlook.com

## Quarterly Report

For the period ending September 30, 2025 (the "Reporting Period")

### Outstanding Shares

The number of shares outstanding of our Common Stock was:

381,209,195 as of September 30, 2025 (Current Reporting Period Date or More Recent Date)

381,209,195 as of June 30, 2025 (Most Recent Completed Fiscal Year End)

### Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### Change in Control

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes:  No:

---

<sup>4</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

The current name of the issuer is "Aoxing Pharmaceutical Company, Inc."

The issuer's name was "China Aoxing Pharmaceutical Co., Inc." until March 2010.

The issuer's name was "Central American Equities Corp." until July 2006.

Current State and Date of Incorporation or Registration: FL, incorporated on 1/23/1996

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

The issuer has been domiciled in FL since incorporation. In September 2019, the entity became inactive with the state of FL for failure to file required annual reports. On August 11<sup>th</sup> 2023, the Custodian reinstated the entity in FL and appointed a new Registered Agent. The entity remains in active status.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

N/A

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On September 12<sup>th</sup> 2024, a collective group of buyers entered into a Securities Purchase Agreement for 305,000,000 shares of Common Stock representing 80% control of the Company, which was closed subsequent to the period covered by this report.

On June 20, 2025, AOXG has acquired InfoEd Tech Limited, a Hong Kong-based EdTech innovator co-founded by Dr. Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurological pharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move capitalizes on soaring demand for accessible education in a region where language barriers stifle learning for millions.

Address of the issuer's principal executive office:

Flat F, 9/F, Block 25, South Horizons,  
Apleichau, Hong Kong

Address of the issuer's principal place of business:

*Check if principal executive office and principal place of business are the same address:*

---

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

On June 28th 2023, the Eleventh Judicial Circuit Court in Miami-Dade County, Florida, entered an Order appointing David Duarte as Custodian of Aoxing Pharmaceutical Company, Inc. (case number: 2022-021295-CA-01). Pursuant to the order, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and its shareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholders meeting, filing of disclosures with OTC Markets, filing of tax returns, disclosure of capital structure and/or business plan, and to exercise the corporate powers of the Company and its board of directors or officers.

On February 2nd 2024, the Eleventh Judicial Circuit Court granted the Custodian's Motion to Discharge, and on February 5th the Order Discharging Custodian and Termination of Custodianship was entered and control of the Company was returned to its Board of Directors.

## 2) Security Information

### **Transfer Agent**

Name: Olde Monmouth Stock Transfer CO., Inc.  
Phone: (732) 872-2727  
Email: matt@oldemonmouth.com  
Address: 200 Memorial Pkwy, Atlantic Heights, NJ 07716

### **Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	AOXG
Exact title and class of securities outstanding:	Common
CUSIP:	03740A106
Par or stated value:	0.0001
Total shares authorized:	750,000,000
Total shares outstanding:	381,209,195
Total number of shareholders of record:	290
	<u>as of date: September 30, 2025</u>

*Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.*

---

### **Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	Preferred
Par or stated value:	.0001
Total shares authorized:	10,000,000
Total shares outstanding:	0
Total number of shareholders of record:	<u>N/A</u>
	<u>as of date: September 30, 2025</u>

*Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.*

---

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

- 1. For common equity, describe any dividend, voting and preemption rights.**

Each common share receives one vote. There are no dividend or preemption rights.

- 2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

N/A

- 3. Describe any other material rights of common or preferred stockholders.**

N/A

- 4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

N/A

**3) Issuance History**

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

**A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u> <u>Date 6/30/2022</u> common: <u>76,209,195</u> Preferred: _____			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>9/19/2023</u>	<u>New Issuance</u>	<u>265,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>David Duarte</u>	<u>Corporate Revival Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>99,800</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>CHIM PO HUNG RAMEN</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>13,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>HO BO MAN MANDY</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>12,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>LIAO MEI YI</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>LAU CHUNG YUEN</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>4,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>CAREN DENISE CURRIER</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/02/2024</u>	<u>New Issuance</u>	<u>900,200</u>	<u>Common</u>	<u>0.0001</u>	<u>Yes</u>	<u>YIP CHI HO</u>	<u>Share Purchase Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> <u>Date 06/30/2025</u> Common: <u>381,209,195</u> Preferred: _____									

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

## B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

**Total Outstanding Balance:**

---

**Total Shares:**

Any additional material details, including footnotes to the table are below:

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

AOXG has acquired InfoEd Tech Limited, a Hong Kong-based EdTech innovator co-founded by Dr. Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurological pharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move capitalizes on soaring demand for accessible education in a region where language barriers stifle learning for millions..

B. List any subsidiaries, parent company, or affiliated companies.

InfoEd Tech Limited, a Hong Kong-based EdTech innovator.

<sup>5</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

C. Describe the issuers' principal products or services.

InfoEd Tech Limited, a Hong Kong-based EdTech innovator co-founded by Dr. Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurological pharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move capitalizes on soaring demand for accessible education in a region where language barriers stifle learning for millions..

**5) Issuer's Facilities**

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

company has no facilities at this time.

**6) All Officers, Directors, and Control Persons of the Company**

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
CHUN FAI LO	CEO/President	Apleichau, Hong Kong	208,926,200	Common	54.806%
PO HUNG RAMEN CHIM	Vice President, Treasurer	Quarry Bay, Hong Kong	56,173,600	Common	14.736%


Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

N/A

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

N/A

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator or a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

N/A

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

N/A

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

**8) Third Party Service Providers**

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:  
Address 1: TBD  
Address 2:  
Phone:  
Email:

Accountant or Auditor

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

Investor Relations

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name:  
Firm:  
Nature of Services:  
Address 1:  
Address 2:  
Phone:  
Email:

## 9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Caren Currier  
Title: Consulting  
Relationship to Issuer: Consulting

B. The following financial statements were prepared in accordance with:

IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Caren Currier  
Title: Consulting  
Relationship to Issuer: Consulting

Describe the qualifications of the person or persons who prepared the financial statements:<sup>6</sup> 25+ years experience

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

### Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

---

<sup>6</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Lo Chun Fai certify that:

1. I have reviewed this Disclosure Statement for Aoxing Pharmaceutical Company, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 18, 2025 [Date]

/s/Lo Chun Fai [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]"")

### *Principal Financial Officer:*

I, PO HUNG RAMEN CHIM certify that:

1. I have reviewed this Disclosure Statement for Aoxing Pharmaceutical Company, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 18, 2025 [Date]

/s/PO HUNG RAMEN CHIM [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]"")

**AOXG**  
**Balance Sheet Prev Year Comparison**  
**As of September 30, 2025**

	<u>Sep 30, 25</u>	<u>Sep 30, 24</u>
<b>ASSETS</b>		
<b>Current Assets</b>		
Checking/Savings	23,941.93	0.00
Accounts Receivable	0.00	0.00
<b>Other Current Assets</b>		
HL&L Holding - Deposit	102,050.00	0.00
Prepaid Taxes	0.00	0.00
Reimbursable Expense	0.00	0.00
Undeposited Funds	0.00	0.00
<b>Total Other Current Assets</b>	<b>102,050.00</b>	<b>0.00</b>
<b>Total Current Assets</b>	<b>125,991.93</b>	0.00
Fixed Assets	0.00	0.00
Other Assets	0.00	0.00
<b>TOTAL ASSETS</b>	<b>125,991.93</b>	<b>0.00</b>
<b>LIABILITIES &amp; EQUITY</b>		
<b>Liabilities</b>		
<b>Current Liabilities</b>		
Accounts Payable	0.00	20,450.00
Credit Cards	0.00	0.00
<b>Other Current Liabilities</b>		
Accrued Expenses	1,800.00	0.00
Due to Related Party	16,276.01	0.00
Loan - CHIM Po Hung Ramen	51,090.00	0.00
Loan - LO Chun Fai Frankie	51,090.00	0.00
Payroll Liabilities	0.00	0.00
Stock Liability-Net	0.00	<b>42,088.00</b>
<b>Total Other Current Liabilities</b>	<b>120,256.01</b>	<b>42,088.00</b>
<b>Total Current Liabilities</b>	<b>120,256.01</b>	62,538.00
Long Term Liabilities	0.00	0.00
<b>Total Liabilities</b>	<b>120,256.01</b>	62,538.00
<b>Equity</b>		
Additional Paid in Capital	73,648,951.00	73,648,951.00
Common Stock	38,121.00	34,121.00
Opening Balance Equity	0.00	0.00
Owners Draw	0.00	0.00
Retained Earnings	-73,681,336.08	<b>-73,745,610.00</b>
<b>Total Equity</b>	<b>5,735.92</b>	<b>-62,538.00</b>
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>125,991.93</b>	<b>0.00</b>

**AOXG**  
**Profit & Loss Prev Year Comparison**  
**July through September 2025**

	<u>Jul - Sep 25</u>	<u>Jul - Sep 24</u>
<b>Ordinary Income/Expense</b>		
<b>Income</b>	2,080.00	0.00
<b>Cost of Goods Sold</b>	0.00	0.00
<b>Gross Profit</b>	<u>2,080.00</u>	<u>0.00</u>
<b>Expense</b>		
<b>Advertising and Promotion</b>	0.00	0.00
<b>Automobile Expense</b>	0.00	0.00
<b>Bank Fees</b>	0.00	0.00
<b>Bank Service Charges</b>	0.00	0.00
<b>Business Licenses and Permits</b>	0.00	0.00
<b>Cleaning</b>	0.00	0.00
<b>Commission</b>	0.00	0.00
<b>Computer and Internet Expenses</b>	351.14	0.00
<b>Continuing Education</b>	0.00	0.00
<b>Depreciation Expense</b>	0.00	0.00
<b>Diploma Fees</b>	2,080.00	0.00
<b>Donations</b>	0.00	0.00
<b>Dues and Subscriptions</b>	100.00	0.00
<b>Insurance Expense</b>	0.00	0.00
<b>Interest Expense</b>	0.00	0.00
<b>Meals and Entertainment</b>	0.00	0.00
<b>Medical</b>	0.00	0.00
<b>Office Supplies</b>	0.00	0.00
<b>Payroll Expenses</b>	0.00	0.00
<b>Personal</b>	0.00	0.00
<b>Postage and Delivery</b>	0.00	0.00
<b>Professional Fees</b>	1,300.00	0.00
<b>Property Taxes</b>	0.00	0.00
<b>Rent Expense</b>	0.00	0.00
<b>Repairs and Maintenance</b>	0.00	0.00
<b>Telephone Expense</b>	0.00	0.00
<b>Travel Expense</b>	688.04	0.00
<b>Utilities</b>	0.00	0.00
<b>Total Expense</b>	<u>4,519.18</u>	<u>0.00</u>
<b>Net Ordinary Income</b>	<u>-2,439.18</u>	<u>0.00</u>
<b>Other Income/Expense</b>		
<b>Other Income</b>	1.01	0.00
<b>Other Expense</b>	0.00	0.00
<b>Net Other Income</b>	<u>1.01</u>	<u>0.00</u>
<b>Net Income</b>	<u><u>-2,438.17</u></u>	<u><u>0.00</u></u>

**AOXG**  
**Statement of Cash Flows**  
**July through September 2025**

	<u>Jul - Sep 25</u>	<u>Jul - Sep 24</u>
<b>OPERATING ACTIVITIES</b>		
Net Income	-2,438.17	0.00
Adjustments to reconcile Net Income to net cash provided by operations:		
Accounts Receivable	0.00	0.00
HL&L Holding - Deposit	-102,050.00	0.00
Prepaid Taxes	0.00	0.00
Reimbursable Expense	0.00	0.00
Accounts Payable	0.00	1,625.00
Accrued Expenses	100.00	0.00
Due to Related Party	0.00	0.00
Loan - CHIM Po Hung Ramen	51,090.00	0.00
Loan - LO Chun Fai Frankie	51,090.00	0.00
Payroll Liabilities	0.00	0.00
Stock Liability-Net	<u>0.00</u>	<u>0.00</u>
Net cash provided by Operating Activities	<u>-2,208.17</u>	<u>1,625.00</u>
<b>INVESTING ACTIVITIES</b>		
Accumulated Depreciation	0.00	0.00
Furniture and Equipment	<u>0.00</u>	<u>0.00</u>
Net cash provided by Investing Activities	<u>0.00</u>	<u>0.00</u>
<b>FINANCING ACTIVITIES</b>		
Additional Paid in Capital	0.00	0.00
Common Stock	0.00	0.00
Opening Balance Equity	0.00	0.00
Owners Draw	0.00	0.00
Retained Earnings	<u>0.00</u>	<u>-1,625.00</u>
Net cash provided by Financing Activities	<u>0.00</u>	<u>-1,625.00</u>
Net cash increase for period	-2,208.17	0.00
Cash at beginning of period	26,150.10	0.00
Cash at end of period	<u><b>23,941.93</b></u>	<u><b>0.00</b></u>

**AOXING PHARMACEUTICAL COMPANY**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(Unaudited)**

	Common Stock		Preferred Stock		Additional	Accumulated	Total Equity
	Shares	Amount	Shares	Amount	Paid -in Capital	(Deficit)	(Deficit)
Balance on December 31, 2022	76,209,195	76,209			73,648,951	-73,725,160	—
Net loss	—	—				—	—
Balance on March 31, 2023	76,209,195	76,209			73,648,951	-73,725,160	—
Net loss	—	—				-4,000	-4,000
Balance on June 30, 2023	76,209,195	76,209			73,648,951	-73,729,160	-4,000
Net loss	—	—				-8,725	-8,725
Amendment of Par Value to .0001		-68,588				—	-68,588
Issuance of Shares at Par	265,000,000	26,500				—	26,500
Balance on Sept 30, 2023	341,209,195	34,121			73,648,951	-73,737,885	-54,813
Net loss	—	—				-4,682	-4,682
Balance on Dec 31, 2023	341,209,195	34,121			73,648,951	-73,742,567	-59,495
Net Loss	—	—				-1,018	-1,018
Balance on March 31, 2024	341,209,195	34,121			73,648,951	-73,743,585	-60,513
Net Loss	—	—				-400	-400
Balance on June 30, 2024	341,209,195	34,121			73,648,951	-73,743,985	-60,913
Net Loss						-1,625	-1,625
Balance on September 30, 2024	341,209,195	34,121			73,648,951	-73,745,610	-62,538
Net Loss	40,000,000	4,000				56,938	60,938
Balance on December 31, 2024	381,209,195	38,121			73,648,951	-73,688,672	-1,600
Net Loss	0	0				7,666	7,666
Balance on March 31, 2025	381,209,195	38,121			73,648,951	-73,681,006	6,066
Net Loss	0	0				2,108	2,108
Balance on June 30, 2025	381,209,195	38,121			73,648,951	-73,678,898	8,174
Net Loss	0	0				-2,438	-2,438
Balance on September 30, 2025	381,209,195	38,121			73,648,951	-73,681,336	5,736

**AOXING PHARMACEUTICAL COMPANY, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR THE QUARTER ENDED SEPTEMBER 30, 2025**  
**(Unaudited)**

**NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS**

Aoxing Pharmaceutical Company, Inc. (the “Company,” “we,” “us” or “our”), a Florida corporation, has a fiscal year end of June 30<sup>th</sup> and is listed on the OTC Pink Markets under the trading symbol AOXG. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Florida Secretary of State, hold an annual meeting of stockholders and pay its annual tax from 2019 to 2022 which resulted in its Florida charter being administratively dissolved. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In November 2022, a shareholder filed a petition for custodianship with the Eleventh Circuit Court, Miami-Dade County, Florida and was appointed as the Custodian of the Company in June 2023. The custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder information hence the Company’s outstanding common shares were reflected in the equity section of the accompanying unaudited financial statements.

The company was incorporated in the State of Florida in January 1996 as Central American Equities Corp. The issuer changed its name to China Aoxing Pharmaceutical Co., Inc. in July 2006. The issuer then changed its name to Aoxing Pharmaceutical Company, Inc. in March, 2010.

On September 16, 2022, David Duarte, a shareholder of the Company, caused demands for compliance with Florida Statutes Chapter 607 to be sent to the address listed for the Registered Agent of Aoxing, with the Florida Secretary of State. On November 4<sup>th</sup>, 2022, David Duarte filed a petition against the Company in the Eleventh Circuit Court of Miami-Dade County, Florida, entitled “In the Matter of Aoxing Pharmaceutical Company, Inc. a Florida corporation,” case number 2022-021295-CA-01.

On June 28<sup>th</sup>, 2023 the District Court of Miami-Dade County, Florida entered an Order Granting Application for Appointment of David Duarte as Custodian of the Company. Pursuant to the order, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and its shareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholders meeting, filing of disclosures with OTC Markets, filing of tax returns, disclosure of capital structure and/or business plan, and to exercise the corporate powers of the Company and its board of directors or officers.

On August 11<sup>th</sup>, 2023, the Custodian appointed David Duarte as President & CEO, Secretary, Treasurer, and Director of the Company, appointed a new Registered Agent, and reinstated the entity which brought the Company active and back into good standing with the State of Florida.

On August 11<sup>th</sup>, 2023, the Custodian increased the common Authorized Shares to 750,000,000, increased the preferred Authorized Shares to 10,000,000, and amended par value of both classes to .0001. On Sept 19<sup>th</sup>, 2023, the Custodian issued to himself 265,000,000 shares of common stock, par value .0001, for consideration of Corporate Revival Services performed.

On October 2, 2024, 40,000,000 shares were issued as part of the change of control

On June 20, 2025, AOXG has acquired InfoEd Tech Limited, a Hong Kong-based EdTech innovator co-founded by Dr. Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurological pharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move capitalizes on soaring demand for accessible education in a region where language barriers stifle learning for millions. Directors have reached a consensus to appoint Lo Chun Fai and/or Chim Po Hung Ramen as the management team for the subsidiary.

## NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

### Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

### Stock-based Compensation.

In June 2018, the FASB issued ASU 2018-07, *Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting*. ASU 2018-07 allows companies to account for non-employee awards in the same manner as employee awards. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods.

### Related Party Transactions

Under ASC 850 "Related Party Transactions" an entity or person is considered to be a "related party" if it has control, significant influence or is a key member of management personnel or affiliate. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The Company, in accordance with ASC 850 presents disclosures about related party transactions and outstanding balances with related parties.

### Derivative Financial Instruments

The Company evaluates its convertible notes to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

### Fair Value of Financial Instruments

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America under U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

- Level 1: Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
- Level 2: Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
- Level 3: Pricing inputs that are generally unobservable inputs and not corroborated by market data.

The carrying amount of the Company's financial assets and liabilities, such as cash, prepaid expenses and accrued expenses

approximate their fair value because of the short maturity of those instruments. The Company's notes payable approximate the fair value of such instruments as the notes bear interest rates that are consistent with current market rates.

#### Basic and Diluted Income (Loss) Per Share

The Company computes income (loss) per share in accordance with FASB ASC 260. Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period.

#### Income Taxes

Income taxes are provided for the tax effects of the transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to tax net operating loss carryforwards. The deferred tax assets and liabilities represent the future tax return consequences of these differences, which will either be taxable or deductible when assets and liabilities are recovered or settled, as well as operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established against deferred tax assets when in the judgment of management, it is more likely than not that such deferred tax assets will not become available. Because the judgment about the level of future taxable income is dependent to a great extent on matters that may, at least in part, be beyond the Company's control, it is at least reasonably possible that management's judgment about the need for a valuation allowance for deferred taxes could change in the near term.

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits" is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement standards. As of September 30, 2025 and 2024, no liability for unrecognized tax benefits was required to be reported.

#### Recently Issued Accounting Pronouncements

The Company has implemented all new applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

#### NOTE 3 - GOING CONCERN

The Company's financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As of September 30 2025, the Company has no source of revenue and has an accumulated deficit of approximately \$73,681,336 and requires additional funds to support its operations and to achieve its business development goals, the attainment of which are not assured.

These factors and uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might incur in the event the Company cannot continue in existence. Management intends to seek additional capital from new equity securities offerings, debt financing and debt restructuring to provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. However, management can give no assurance that these funds will be available in adequate amounts, or if available, on terms that would be satisfactory to the Company. The timing and amount of the Company's capital requirements will depend on a number of factors, including maintaining its status as a public company and supporting shareholder and investor relations.

#### NOTE 4 – PROCEEDS FROM RELATED PARTY

All related party notes were cleared upon transfer of ownership

## NOTE 5 – OTHER SIGNIFICANT EVENTS

AOXG has acquired **InfoEd Tech Limited**, a Hong Kong-based EdTech innovator co-founded by Dr. Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurological pharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move capitalizes on soaring demand for accessible education in a region where language barriers stifle learning for millions.

## NOTE 6 – SUBSEQUENT EVENTS

None